Clover Biopharmaceuticals, a clinical-stage biotech developing novel vaccines and biologic therapeutic candidates, has started construction on a new R&D Center in Zhangjiang Biotech and Pharmaceutical Industrial Base in Shanghai.
An expert speaking during the industry event offers insight and perspective on the flurry of CDMO deal-making in recent months, and what might lie ahead.
Biopharma industry in the US is rooted in a strong R&D sector, with the employment percentage being three times larger than the industry average, suggests PhRMA.
